公开(公告)号：US09498527B2

公开(公告)日：2016-11-22

申请号：US13856002

申请日：2013-04-03

Applicant: NITTO DENKO CORPORATION ,  OSAKA UNIVERSITY

Inventor： Masahiro Fukasaka ,  Arimichi Okazaki ,  Daisuke Asari ,  Mitsuhiko Hori ,  Shizuo Akira ,  Osamu Takeuchi

IPC: A61K39/39 ,  A61K39/145 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/5252 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/575 ,  C12N7/00 ,  C12N2710/00034 ,  C12N2760/16034 ,  C12N2760/16134 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412

Abstract: An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.

Abstract translation: 提供可用于感染性疾病的预防或治疗剂，有效诱导全身免疫应答或粘膜免疫应答的口服给药的疫苗组合物。 一种用于给予人或动物口腔的疫苗组合物，所述疫苗组合物含有至少一种源自感染性疾病的抗原，以及至少一种选自toll样受体4（TLR4）激动剂 ，一种toll样受体2/6（TLR2 / 6）激动剂和环二核苷酸，或其衍生物或盐。

公开(公告)号：US09732107B2

公开(公告)日：2017-08-15

申请号：US14895314

申请日：2014-06-04

Applicant: OSAKA UNIVERSITY ,  NIPPON ZENYAKU KOGYO CO., LTD.

Inventor： Shizuo Akira ,  Ken Ishii ,  Cevayir Coban ,  Yoshikatsu Igari ,  Yasumasa Kano ,  Akina Otsuki

IPC: C07D487/22 ,  C07F15/02 ,  A61K39/39

CPC classification number: C07F15/025 ,  A61K39/39 ,  C07B2200/13 ,  C07D487/22

Abstract: This invention provides a method of preparing a β-hematin crystal comprising a step of heating, the β-hematin crystal obtained by such method, and a vaccine adjuvant composition containing the β-hematin crystal. The β-hematin crystal has a needle-like morphology, it has an average particle size of 0.6 to 1.2 μm, and it exhibits main peaks characteristics for angles of diffraction (2θ) of 7.4°, 12.2°, 21.6°, and 24.1° in an X-ray diffraction pattern obtained by powder X-ray diffractometry with Cu—Kα rays (with each peak including a plus-minus 0.2° diffraction angle).

公开(公告)号：US20160296613A1

公开(公告)日：2016-10-13

申请号：US15189234

申请日：2016-06-22

Applicant: Osaka University

Inventor： Shizuo Akira ,  Ken Ishii ,  Cevayir Coban

IPC: A61K39/015 ,  G01N33/569

CPC classification number: A61K39/015 ,  A01K2267/0387 ,  A61K2039/572 ,  G01N33/56905 ,  G01N2333/445 ,  G01N2333/70596 ,  G01N2500/10 ,  Y02A50/58

Abstract: The instant invention is to provide a method for detecting and measuring malaria infection utilizing the induction by hemozoin (HZ); a method for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection using the method for detecting and measuring; and a means for regulating the induction of innate immunity using the HZ, synthetic HZ, or derivatives thereof as an adjuvant or immunostimulant. Malaria infection is detected and measured of by detecting and measuring HZ-induced, TLR9-mediated, and MyD88-dependent innate immune activity. The detection and measurement of malaria infection can be used to diagnose malaria infection. The method for detecting and measuring is also used for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection. Further, HZ, synthetic HZ, or derivatives thereof are used as an adjuvant or immunostimulant to regulate HZ-induced innate immune induction.

Abstract translation: 本发明是提供一种利用血红素（HZ）的诱导检测和测量疟疾感染的方法; 使用检测和测量方法筛选疟疾感染疫苗的方法和用于疟疾感染的预防或治疗剂; 以及使用HZ，合成HZ或其衍生物作为佐剂或免疫刺激剂来调节诱导天然免疫的方法。 通过检测和测量HZ诱导的TLR9介导的和MyD88依赖性先天免疫活性来检测和测量疟疾感染。 疟疾感染的检测和测量可用于诊断疟疾感染。 用于检测和测量的方法也用于筛选疟疾感染的疫苗和用于疟疾感染的预防或治疗剂。 此外，HZ，合成HZ或其衍生物用作佐剂或免疫刺激剂以调节HZ诱导的先天免疫诱导。

公开(公告)号：US10172927B2

公开(公告)日：2019-01-08

申请号：US15189234

申请日：2016-06-22

Applicant: Osaka University

Inventor： Shizuo Akira ,  Ken Ishii ,  Cevayir Coban

IPC: A61K39/015 ,  G01N33/569 ,  A61K39/00

Abstract: The instant invention is to provide a method for detecting and measuring malaria infection utilizing the induction by hemozoin (HZ); a method for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection using the method for detecting and measuring; and a means for regulating the induction of innate immunity using the HZ, synthetic HZ, or derivatives thereof as an adjuvant or immunostimulant. Malaria infection is detected and measured of by detecting and measuring HZ-induced, TLR9-mediated, and MyD88-dependent innate immune activity. The detection and measurement of malaria infection can be used to diagnose malaria infection. The method for detecting and measuring is also used for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection. Further, HZ, synthetic HZ, or derivatives thereof are used as an adjuvant or immunostimulant to regulate HZ-induced innate immune induction.

公开(公告)号：US20210198667A1

公开(公告)日：2021-07-01

申请号：US17048063

申请日：2018-11-27

Applicant: Osaka University

Inventor： Takashi Satoh ,  Shizuo Akira

IPC: C12N15/113 ,  A61P11/00 ,  G01N33/68 ,  G01N33/50 ,  C12Q1/6851

Abstract: The purpose of the present invention is to provide a molecule having a significant effect on the development of fibrosis and a substance capable of inhibiting fibrosis. This biomarker for fibrosis comprises RNA binding motif protein 7 (RBM7) and is useful as a biomarker for diagnosis of fibrosis. This fibrosis detection method comprising the step of detecting RBM7 in a biological sample from a subject preferably using an anti-RBM7 antibody is useful for diagnosis of fibrosis. This antifibrotic agent containing a substance which inhibits the expression of RBM7, preferably at least one nucleic acid drug selected from the group consisting of siRNAs, shRNAs, dsRNAs, miRNAs, and antisense nucleic acids against RBM7, is useful for treatment of fibrosis.